[go: up one dir, main page]

ES2050070A1 - Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. - Google Patents

Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.

Info

Publication number
ES2050070A1
ES2050070A1 ES09201523A ES9201523A ES2050070A1 ES 2050070 A1 ES2050070 A1 ES 2050070A1 ES 09201523 A ES09201523 A ES 09201523A ES 9201523 A ES9201523 A ES 9201523A ES 2050070 A1 ES2050070 A1 ES 2050070A1
Authority
ES
Spain
Prior art keywords
peptide
controlled release
prolonged
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09201523A
Other languages
English (en)
Other versions
ES2050070B1 (es
Inventor
Piero Orsolini
Frederic Heimgartner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Publication of ES2050070A1 publication Critical patent/ES2050070A1/es
Application granted granted Critical
Publication of ES2050070B1 publication Critical patent/ES2050070B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE UNA COMPOSICION DESTINADA A LA LIBERACION PROLONGADA Y CONTROLADA DE UNA SUSTANCIA PEPTIDICA DE FORMULA (I). AC-D-NAL-D-PCLPHE-RBS3 SC-SER-TYR-D-CIT-LEU-ARG-PRO-D-ALA-NHSI2 SC (I) EN LA CUAL RBS3 SC DESIGNA D-PAL O D-TRP, QUE CONSISTE EN CONVERTIR UNA SAL DE DICHO PEPTIDO SOLUBLE EN AGUA EN UNA SAL INSOLUBLE Y POSTERIOR TRATAMIENTO DE DICHA SAL INSOLUBLE CON UN POLIMERO BIODEGRADABLE EN SUSPENSION EN UN MEDIO ORGANICO. LA PREPARACION OBJETO DE LA INVENCION PROPORCIONA UNA FORMA OPTIMA DE ADMINISTRACION DE LA SUSTANCIA PEPTIDICA.
ES09201523A 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. Expired - Fee Related ES2050070B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2178/91A CH683149A5 (fr) 1991-07-22 1991-07-22 Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (2)

Publication Number Publication Date
ES2050070A1 true ES2050070A1 (es) 1994-05-01
ES2050070B1 ES2050070B1 (es) 1994-10-01

Family

ID=4227716

Family Applications (2)

Application Number Title Priority Date Filing Date
ES9201522A Expired - Fee Related ES2037621B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable.
ES09201523A Expired - Fee Related ES2050070B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES9201522A Expired - Fee Related ES2037621B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable.

Country Status (40)

Country Link
US (2) US5445832A (es)
JP (2) JP3600252B2 (es)
KR (1) KR930702018A (es)
CN (1) CN1054543C (es)
AT (2) AT408609B (es)
AU (2) AU652844B2 (es)
BE (2) BE1005696A3 (es)
BR (1) BR9205375A (es)
CA (2) CA2074320C (es)
CH (2) CH683149A5 (es)
CZ (1) CZ287585B6 (es)
DE (3) DE4223282A1 (es)
DK (2) DK176219B1 (es)
EE (1) EE03014B1 (es)
ES (2) ES2037621B1 (es)
FI (2) FI106925B (es)
FR (2) FR2680109B1 (es)
GB (2) GB2257973B (es)
GR (2) GR1001446B (es)
HR (1) HRP920229A2 (es)
HU (1) HU218203B (es)
IE (2) IE71199B1 (es)
IL (2) IL102591A (es)
IT (2) IT1259892B (es)
LU (2) LU88150A1 (es)
MX (1) MX9204268A (es)
NL (2) NL194577C (es)
NO (2) NO304057B1 (es)
NZ (1) NZ243643A (es)
PH (1) PH31564A (es)
PL (1) PL169387B1 (es)
PT (2) PT100712B (es)
RU (1) RU2103994C1 (es)
SE (2) SE512609C2 (es)
SI (1) SI9200152B (es)
SK (1) SK280612B6 (es)
TW (1) TW260610B (es)
UA (1) UA35569C2 (es)
WO (1) WO1993001802A1 (es)
ZA (2) ZA925486B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0626170A3 (en) 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacologically active compounds in delayed release agents.
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
EP1073419A4 (en) * 1998-03-18 2009-03-25 Univ Technology Corp COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE.
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
JP2002521343A (ja) * 1998-07-23 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 水溶性ペプチドのカプセル化
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en) 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6317623B1 (en) * 1999-03-12 2001-11-13 Medrad, Inc. Apparatus and method for controlling contrast enhanced imaging procedures
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
ES2292634T3 (es) 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Procedimiento de transicion de fase inducida para la produccion de microparticulas que contienen agentes hidrofilos activos.
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) * 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2516098A1 (en) * 2003-03-05 2004-09-16 Paul S. Hudnut Oxytocin controlled release formulations and methods of using same
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1838305A1 (en) * 2005-01-21 2007-10-03 Richard H. Matthews Radiosensitizer formulations comprising nitrohistidine derivatives
US20080095849A1 (en) * 2005-04-25 2008-04-24 Amgen Inc. Peptide sustained release compositions and uses thereof
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
BRPI0612071A2 (pt) * 2005-06-14 2010-10-19 Baxter Int formulações farmacêuticas para minimizar interações entre fármacos
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
EP1968549B1 (en) * 2005-12-22 2014-05-14 Novartis AG Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
US9301792B2 (en) 2006-01-27 2016-04-05 Stryker Corporation Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
CA2688478C (en) * 2007-06-06 2015-10-27 Debio Recherche Pharmaceutique S.A. Slow release pharmaceutical composition made of microparticles
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
CN102665698A (zh) 2009-12-23 2012-09-12 迪菲安特制药有限责任公司 可用于治疗心血管疾病的联合组合物
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012250776B2 (en) 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
WO2013150384A1 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
BR112014028443B1 (pt) * 2012-05-14 2021-01-19 Teijin Limited composição estéril esterilizada com radiação
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
EA201690732A1 (ru) 2013-10-10 2016-12-30 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
BR112020006136A2 (pt) 2017-09-26 2020-10-06 Nanomi B.V. método para a preparação de micropartículas pela técnica de dupla emulsão
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (fr) * 1980-10-06 1982-04-09 Stolle Res & Dev Procede de microcapsulation
ES2009346A6 (es) * 1987-09-21 1989-09-16 Debiopharm Sa Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
FR2649319A1 (fr) * 1989-07-07 1991-01-11 Sandoz Sa Formulations a liberation prolongee de peptides solubles dans l'eau
FR2650182A1 (fr) * 1989-07-28 1991-02-01 Debiopharm Sa Procede de preparation d'une composition pharmaceutique sous forme de microparticules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (es) * 1972-01-26 1977-01-27
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
CH672887A5 (es) * 1987-10-14 1990-01-15 Debiopharm Sa
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
CH681425A5 (es) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (fr) * 1980-10-06 1982-04-09 Stolle Res & Dev Procede de microcapsulation
ES2009346A6 (es) * 1987-09-21 1989-09-16 Debiopharm Sa Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
FR2649319A1 (fr) * 1989-07-07 1991-01-11 Sandoz Sa Formulations a liberation prolongee de peptides solubles dans l'eau
FR2650182A1 (fr) * 1989-07-28 1991-02-01 Debiopharm Sa Procede de preparation d'une composition pharmaceutique sous forme de microparticules

Also Published As

Publication number Publication date
ATA148992A (de) 1997-06-15
SE512609C2 (sv) 2000-04-10
IL102591A0 (en) 1993-01-14
ES2037621A1 (es) 1993-06-16
HRP920229A2 (en) 1996-04-30
CN1054543C (zh) 2000-07-19
US5445832A (en) 1995-08-29
SE9202213L (sv) 1993-01-23
CN1070344A (zh) 1993-03-31
JP3600252B2 (ja) 2004-12-15
PH31564A (en) 1998-11-03
SE9202213D0 (sv) 1992-07-21
GB2257909A (en) 1993-01-27
AT403348B (de) 1998-01-26
NL9201310A (nl) 1993-02-16
RU2103994C1 (ru) 1998-02-10
HU218203B (hu) 2000-06-28
AU2043692A (en) 1993-01-28
NO304057B1 (no) 1998-10-19
FI923321L (fi) 1993-01-23
MX9204268A (es) 1994-03-31
SE9202212L (sv) 1993-01-23
IE71199B1 (en) 1997-02-12
LU88151A1 (fr) 1993-02-15
NL194576C (nl) 2002-08-05
SE512670C2 (sv) 2000-04-17
NO922885L (no) 1993-01-25
NL9201309A (nl) 1993-02-16
SI9200152B (sl) 1998-06-30
JP2842736B2 (ja) 1999-01-06
FI923320A0 (fi) 1992-07-21
CZ66093A3 (en) 1994-01-19
FR2679450A1 (fr) 1993-01-29
PT100713A (pt) 1993-08-31
AU2043792A (en) 1993-01-28
DK93992A (da) 1993-01-23
AU652844B2 (en) 1994-09-08
DK176219B1 (da) 2007-02-26
ATA148892A (de) 2001-06-15
WO1993001802A1 (fr) 1993-02-04
GB2257973B (en) 1996-02-28
NL194576B (nl) 2002-04-02
IE69967B1 (en) 1996-10-16
DK176218B1 (da) 2007-02-26
IE922366A1 (en) 1993-01-27
SK280612B6 (sk) 2000-05-16
EE03014B1 (et) 1997-08-15
ZA925485B (en) 1993-04-28
FR2680109A1 (fr) 1993-02-12
ITBS920092A0 (it) 1992-07-21
AT408609B (de) 2002-01-25
IL102591A (en) 1997-06-10
GR1002548B (el) 1997-01-28
CA2074322C (en) 2003-04-08
UA35569C2 (uk) 2001-04-16
CA2074322A1 (en) 1993-01-23
HU9301186D0 (en) 1993-07-28
TW260610B (es) 1995-10-21
NO922886L (no) 1993-01-25
CZ287585B6 (cs) 2000-12-13
PT100712B (pt) 1999-07-30
DK93892D0 (da) 1992-07-21
JPH05221855A (ja) 1993-08-31
IT1259891B (it) 1996-03-28
DE4223284A1 (de) 1993-01-28
CH683149A5 (fr) 1994-01-31
PT100713B (pt) 1999-07-30
DE9219084U1 (de) 1997-09-25
CA2074320C (en) 1999-04-06
CA2074320A1 (en) 1993-01-23
BE1005697A5 (fr) 1993-12-21
DE4223282A1 (de) 1993-01-28
FI106925B (fi) 2001-05-15
NL194577C (nl) 2002-08-05
BR9205375A (pt) 1994-03-08
SE9202212D0 (sv) 1992-07-21
FI105318B (fi) 2000-07-31
IE922367A1 (en) 1993-01-27
IL102590A0 (en) 1993-01-14
NL194577B (nl) 2002-04-02
GB2257909B (en) 1996-01-10
DK93992D0 (da) 1992-07-21
PT100712A (pt) 1993-10-29
GB9215479D0 (en) 1992-09-02
ZA925486B (en) 1993-04-28
IT1259892B (it) 1996-03-28
IL102590A (en) 1997-07-13
NO922885D0 (no) 1992-07-21
PL298504A1 (en) 1994-01-10
GB9215480D0 (en) 1992-09-02
FI923321A0 (fi) 1992-07-21
ITBS920093A1 (it) 1994-01-21
DK93892A (da) 1993-01-23
DE4223284C2 (de) 1997-07-31
CH683592A5 (fr) 1994-04-15
NO922886D0 (no) 1992-07-21
FR2679450B1 (fr) 1995-06-09
FI923320L (fi) 1993-01-23
JPH06172208A (ja) 1994-06-21
ITBS920093A0 (it) 1992-07-21
ES2037621B1 (es) 1994-02-01
ES2050070B1 (es) 1994-10-01
GR920100323A (el) 1993-05-24
GB2257973A (en) 1993-01-27
ITBS920092A1 (it) 1994-01-21
NO304136B1 (no) 1998-11-02
SK38293A3 (en) 1993-08-11
SI9200152A (en) 1993-03-31
GR1001446B (el) 1993-12-30
LU88150A1 (fr) 1993-02-15
KR930702018A (ko) 1993-09-08
FR2680109B1 (fr) 1994-09-02
AU651711B2 (en) 1994-07-28
HUT64234A (en) 1993-12-28
NZ243643A (en) 1993-10-26
BE1005696A3 (fr) 1993-12-21
PL169387B1 (pl) 1996-07-31
US5637568A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
ES2050070A1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
BR9509201A (pt) Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
PT951280E (pt) Microparticulas hidrofilicas e metodos para a sua preparacao
DE69529486D1 (de) Zubereitung mit verzögerter Freisetzung
DE59306812D1 (de) Präparate von fettlöslichen Substanzen
NL195027B (nl) Werkwijze voor het bereiden van microdeeltjes voor langzame afgifte van in water oplosbare peptiden en preparaten daarvan.
ES2113095T3 (es) Preparacion solida de liberacion rapida, su produccion y su uso.
DK74187A (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
DK0737065T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske doseringsformer
CO4600671A1 (es) Formulacion de cafeina de liberacion sostenida
KR970703133A (ko) 중합체 매트릭스 중의 활성제의 고용체 형태로서의 활성제 제제의 제조 방법 및 그에 의해 얻어진 활성제 제제(Process for Producing Active Agent Preparations in the Form of a Solid Solution of the Active Agent in a Polymer Matrix and Active Agent Preparations Obtained Thereby)
MX20055A (es) Procedimiento para la preparacion de una composicion acuosa de ibuprofen y procedimiento para su preparacion.
BR0004152A (pt) Micropartìculas lipófilas contendo um medicamento protéico ou antìgeno e preparado compreendendo o mesmo
WO2002058672A3 (en) Microparticles of biodegradable polymer encapsulating a biologically active substance
KR890007789A (ko) 수용성 펩타이드 및 단백질의 생체분해 가능한 마이크로캡슐의 제조방법 및 이 방법에 의해 수득되는 마이크로캡슐
DK1061948T3 (da) Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
ES2231176T3 (es) Uso de beta-(1,3)-glucanos nanometricos hidrosolubles.
ES2185367T3 (es) Hidrogeles poliionicos a base de xantano y qutosan para la estabilizacion y la separacion contr0ladas de las vitaminas.
ES2018737A6 (es) Composicion plaguicida mejorada y procedimiento para su preparacion.
YU47573B (sh) Postupak za dobivanje čvrstog farmaceutskog preparata
ES2138053T3 (es) Formulacion insecticida solida.
NZ505351A (en) Sustained release water-insoluble matrix comprising protein crosslinked with urea using a crosslinking agent and a bioactive substances such as a trace element
GR1003683B (el) Μεθοδος παρασκευης φυτικου ιδιοσκευασματος για την προληψη της ταλαιπωριας των μαλλιων απο τις χημικες ουσιες της βαφης ή των υγρων κατσαρωματος μαλλιων (περμαναντ).

Legal Events

Date Code Title Description
PC2A Transfer of patent
PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20070723